Rowpar Pharmaceuticals said that an in vitro laboratory analysis found that its CloSys ultrasensitive oral rinse reduced SARS-CoV-2 by up to 98.4% within 30 seconds.
The study was conducted at an independent laboratory, MRI Global in Kansas City. A second independent accredited lab, Microbac Laboratories in Sterling, VA, also produced similar results, according to Rowpar.
The company noted that these initial trials did not include testing of the oral cavity. However, based on these results, Rowpar said it has now launched additional studies to determine whether CloSys over-the-counter products can help lower the transmission of the novel coronavirus from one person to another.
